Sinotherapeutics Inc
SSE:688247
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (19.7), the stock would be worth ¥9.16 (2% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 20 | ¥9.3 |
0%
|
| 3-Year Average | 19.7 | ¥9.16 |
-2%
|
| 5-Year Average | 20.9 | ¥9.7 |
+4%
|
| Industry Average | 7.6 | ¥3.51 |
-62%
|
| Country Average | 13.6 | ¥6.3 |
-32%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Sinotherapeutics Inc
SSE:688247
|
4.2B CNY | 20 | 42.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 17.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 6.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8 |
| Median | 13.6 |
| 70th Percentile | 23.3 |
| Max | 17 898 541.1 |
Other Multiples
Sinotherapeutics Inc
Glance View
Sinotherapeutics, Inc. engages in the research and development, production and sales of high-end generic drugs and Contract Research Organization (CRO) services. The company is headquartered in Shanghai, Shanghai and currently employs 248 full-time employees. The company went IPO on 2022-08-25. The firm's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The firm mainly operates in the domestic market and overseas markets.
